StaR technology
E474947
StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
drug discovery platform
ⓘ
proprietary technology ⓘ protein stabilization technology ⓘ |
| appliesTo | G protein–coupled receptors NERFINISHED ⓘ |
| associatedWith | Sosei Group Corporation NERFINISHED ⓘ |
| basedOn |
protein engineering
ⓘ
thermostabilizing point mutations ⓘ |
| developer | Heptares Therapeutics NERFINISHED ⓘ |
| enables |
biophysical characterization of GPCR–ligand interactions
ⓘ
crystallization of GPCRs ⓘ high-resolution GPCR structures ⓘ screening of small molecules against stabilized GPCRs ⓘ |
| field |
G protein–coupled receptor research
ⓘ
structure-based drug discovery ⓘ |
| fullName | Stabilized Receptor technology NERFINISHED ⓘ |
| goal | to enable drug discovery against previously intractable GPCR targets ⓘ |
| hasCommercialUse |
biotechnology research collaborations
ⓘ
pharmaceutical research ⓘ |
| improves |
stability of GPCRs in detergent solutions
ⓘ
suitability of GPCRs for X-ray crystallography ⓘ suitability of GPCRs for biophysical assays ⓘ |
| intellectualPropertyStatus | patented technology ⓘ |
| owner | Heptares Therapeutics NERFINISHED ⓘ |
| purpose |
enabling detailed structural analysis of GPCRs
ⓘ
enabling structure-based design of ligands ⓘ facilitating fragment-based drug discovery on GPCRs ⓘ stabilization of GPCRs ⓘ |
| relatedTo |
GPCR structural biology
ⓘ
membrane protein crystallography ⓘ structure-based medicinal chemistry ⓘ |
| shortName | StaR NERFINISHED ⓘ |
| supports |
fragment screening on GPCR targets
ⓘ
rational design of GPCR ligands ⓘ structure-based virtual screening ⓘ |
| targetType |
class A GPCRs
ⓘ
class B GPCRs ⓘ class C GPCRs ⓘ membrane proteins ⓘ |
| technologyType |
enabling technology
ⓘ
platform technology ⓘ |
| usedBy | Heptares Therapeutics drug discovery programs ⓘ |
| usedFor |
identification of GPCR agonists
ⓘ
identification of GPCR allosteric modulators ⓘ identification of GPCR antagonists ⓘ lead optimization of GPCR-targeted compounds ⓘ |
| usedIn |
early-stage drug discovery
ⓘ
lead identification ⓘ lead optimization ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.